Cargando…

Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab

The biology and pathogenesis of clear cell carcinoma of the kidney has been extensively investgated, and the role of von Hipple-Landau gene inactivation and tumor associated angiogenesis is now recognized. Development of vascular endothelial growth factor inhibitors and phase 3 clinical trials utili...

Descripción completa

Detalles Bibliográficos
Autor principal: Bukowski, Ronald M
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004565/
https://www.ncbi.nlm.nih.gov/pubmed/21188099
_version_ 1782193997344669696
author Bukowski, Ronald M
author_facet Bukowski, Ronald M
author_sort Bukowski, Ronald M
collection PubMed
description The biology and pathogenesis of clear cell carcinoma of the kidney has been extensively investgated, and the role of von Hipple-Landau gene inactivation and tumor associated angiogenesis is now recognized. Development of vascular endothelial growth factor inhibitors and phase 3 clinical trials utilizing this class of agents has produced a new treatment paradigm for patients with metastatic renal cell carcinoma (RCC). One of the active regimens identified is the combination of bevacizumab and interferon-α. Recently published reports provided evidence of the clinical and biologic activity of this therapy. The current manuscript reviews the background and rationale for the activity of bevacizumab in RCC, and results from recent clinical trials with this agent alone or in combination with targeted agents or cytokines. The role of this therapy in contrast to other targeted agents is reviewed, and the potential utility as well as questions raised by recent studies are discussed.
format Text
id pubmed-3004565
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30045652010-12-23 Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab Bukowski, Ronald M Cancer Manag Res Review The biology and pathogenesis of clear cell carcinoma of the kidney has been extensively investgated, and the role of von Hipple-Landau gene inactivation and tumor associated angiogenesis is now recognized. Development of vascular endothelial growth factor inhibitors and phase 3 clinical trials utilizing this class of agents has produced a new treatment paradigm for patients with metastatic renal cell carcinoma (RCC). One of the active regimens identified is the combination of bevacizumab and interferon-α. Recently published reports provided evidence of the clinical and biologic activity of this therapy. The current manuscript reviews the background and rationale for the activity of bevacizumab in RCC, and results from recent clinical trials with this agent alone or in combination with targeted agents or cytokines. The role of this therapy in contrast to other targeted agents is reviewed, and the potential utility as well as questions raised by recent studies are discussed. Dove Medical Press 2010-03-26 /pmc/articles/PMC3004565/ /pubmed/21188099 Text en © 2010 Bukowski, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Bukowski, Ronald M
Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
title Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
title_full Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
title_fullStr Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
title_full_unstemmed Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
title_short Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
title_sort metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004565/
https://www.ncbi.nlm.nih.gov/pubmed/21188099
work_keys_str_mv AT bukowskironaldm metastaticclearcellcarcinomaofthekidneytherapeuticroleofbevacizumab